NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Mavorixafor for treating WHIM syndrome ID3946

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • Norgine Pharmaceuticals (Mavorixafor) Patient/carer groups • Allergy UK • Anthony Nolan • Asthma + Lung UK • Black Health Agency for Equality • Changing Faces • Genetic Alliance UK • Immunodeficiency UK • International Patient Organisation for Primary Immunodeficiencies • Let's Face It • South Asian Health Foundation • Specialised Healthcare Alliance • UK Primary Immune-deficiency Patient Support Charity (UKPIPS) Healthcare professional groups • Association for Respiratory Technology and Physiology • Association of Respiratory Nurse Specialists • British Association of Dermatologists • British Dermatological Nursing Group • British Infection Association • British Rhinological Society • British Society for Haematology • British Society for Immunology • British Thoracic Society • Infection Prevention Society • National Heart and Lung Institute • Primary Care Dermatology Society • Primary Care Respiratory Society UK • Royal College of General Practitioners	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehova's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Welsh Government Possible comparator companies • Amarox (plerixafor) • Amgen (filgrastim, pegfilgrastim) • Chugai Pharma (lenograstim) • Napp Pharmaceuticals (pegfilgrastim) • Pfizer (filgrastim) • Sandoz (filgrastim) • Seacross Pharmaceuticals (plerixafor) • Teva Pharma (lipegfilgrastim) • Tillomed Laboratories (plerixafor) Relevant research groups • British Association for Lung Research • Cochrane Airways Group • Cochrane Skin Group

Provisional Consultees	**Provisional Commentators (no right to submit or appeal)**
• Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <u>Others</u> • Department of Clinical Immunology, Royal Free Hospital • Department of Health and Social Care • Immunology Department, Great Ormond Street Hospital • NHS England • NHS England – Genomics Unit • Paediatric Infectious Diseases Research Group, St George's University Hospitals NHS Foundation Trust	• Dermatrust • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

